Kim Nguyen Chi reports honoraria from Janssen, Astellas Pharma, Bayer, AstraZeneca, Roche, Merck, POINT Biopharma, Amgen, BMS GmbH & Co. KG, Novartis, and Pfizer; consulting or advisory roles for Astellas Pharma, Janssen, Amgen, Bayer, AstraZeneca, Roche, POINT Biopharma, Merck, and BMS GmbH & Co. KG; and research funding from Janssen, Astellas Pharma, Bayer, Sanofi, BMS, Merck, Roche, AstraZeneca, Novartis, Pfizer, and ESSA. Rana R McKay reports consulting or advisory roles for Janssen, Novartis, Tempus, Exelixis, Pfizer, BMS, Astellas Medivation, Dendreon, Bayer, Sanofi, Merck, Vividion Therapeutics, Calithera Biosciences, AstraZeneca, Myovant Sciences, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seagen, Telix Pharmaceuticals, Lilly, Blue Earth Diagnostics, Ambrx, Arcus Biosciences, Sumitomo Pharma Oncology, Eisai, and NeoMorph; and research funding from Bayer, Tempus, AstraZeneca, Exelixis, BMS, Oncternal Therapeutics, Artera. Shahneen Sandhu reports consulting/advisory roles with AbbVie, AstraZeneca, Bristol Myers Squibb, Merck Sharp & Dohme, Novartis, Roche/Genentech, Janssen, AdvanCell and Skyline Diagnostics; honoraria to the institution from Abbvie, AstraZeneca, Bristol Myers Squibb, Janssen, Merck, Merck Serono, Novartis, AdvanCell, and Skyline Diagnostics; institutional research funding from Amgen, AstraZeneca, Bristol Myers Squibb, Endocyte/Advanced Accelerator Applications, Genentech/Roche, Merck, Novartis, Pfizer, and Senhwa Biosciences; and stock ownership in AdvanCell. Jose A Arranz reports consulting or advisory roles for Pfizer, Astellas Pharma, MSD Oncology, BMS, Merck, AstraZeneca, Bayer, Novartis, and Recordati; speakers bureau for Merck and Pfizer; and research funding from BMS. Philippe Barthélémy reports advisory boards, speakers bureau, honoraria from Bristol Myers Squibb, Pfizer, MSD, Roche, IPSEN, Eisai, Janssen Cilag, Bayer, Amgen, AstraZeneca, Novartis, Gilead, Merck, and Astellas. Boris Hadaschik reports consulting fees from Janssen, Bayer, ABX, Astellas, Merck, Amgen, MSD/Pfizer, Novartis, BMS, Monrol, Onkowissen, POINT Biopharma, Ipsen, AstraZeneca, Lightpoint Medical, Telix, and Accord Healthcare; travel support from AstraZeneca, BMS, Janssen, Bayer, and Ipsen; grants or contracts from Janssen, Deutsche Forschungsgesellschaft, Novartis, and BMS; and participation on data safety monitoring boards for Janssen and ABX. Nobuaki Matsubara reports consulting or advisory roles for Sanofi, Janssen, AstraZeneca, Lilly, Amgen, Seagen, and Pfizer; honoraria from Sanofi; and research funding from Janssen, MSD, Bayer Yakuhin, Chugai Pharma, AstraZeneca, Astellas Pharma, Bayer, Amgen, Takeda, Lilly, Eisai, Roche/Genentech, Seagen, Novartis, and AbbVie. Neal D Shore reports employment at GenesisCare; consulting or advisory roles for Bayer, Janssen, Dendreon, Tolmar, Ferring, Medivation/Astellas, Amgen, Pfizer, AstraZeneca, Astellas Pharma, Merck, BMS, Exact Imaging, InVitae, MDxHealth, Myriad Genetics, Propella Therapeutics, Sanofi, Urogen pharma, Specialty Networks, Peerview, Clarity Pharmaceuticals, Lantheus Medical Imaging, Lilly, Photocure, Telix Pharmaceuticals, Arquer Diagnostics, Minomic, Novartis, PlatformQ Health, Promaxo, Protara Therapeutics, Fize Medical, Accord Research, Antev, Aura Biosciences, Bioprotect, Sumitomo Pharma Oncology, Siemens, Alessa Therapeutics, CG Oncology, Glytherix, Tutelix; research funding from Abbvie, Amgen, Astellas Pharma, AstraZeneca, Bayer, BMS, Boston Scientific, Clovis Oncology, Dendreon, Exact Imaging, Ferring, Foundation Medicine, Invitae, Janssen, MDxHealth, Merck, Myovant Sciences, Myriad Genetics, Nymox, Pfizer, Sesen Bio, Tolmar, CG Oncology, DisperSol, FORMA Therapeutics, Guardant Health, Jiangsu Yahong Meditech, Novartis, Pacific Edge, POINT Biopharma, Propella Therapeutics, Seagen, MT group, Theralase, Very, Zenflow, Advantagene, Aragon Pharmaceuticals, Endocyte, Exelixis, FKD Therapies, Genentech, ISTARI Oncology, Medivation, OncoCellMDx, ORIC Pharmaceuticals, Palette Life Sciences, Plexxikon, RhoVac, Steba Biotech, Urogen Pharma, Urotronic, US Biotest, and Vaxiion. Dingwei Ye reports no conflicts of interest. Teresa Cascella, Irina Irincheeva, and Stephanie Kreiser report employment and stock ownership with BMS. Antoine Thiery-Vuillemin reports employment and stock ownership with BMS; honoraria from Roche, MSD, Johnson & Johnson, Astellas Pharma, Ipsen, AstraZeneca, and Novartis; consulting or advisory role for Roche, MSD, Johnson & Johnson, BMS, Ipsen AstraZeneca, and Novartis; and travel accommodations from Roche, MSD, Johnson & Johnson, BMS, Astellas Pharma, Ipsen, and AstraZeneca. Dana E Rathkopf reports consulting or advisory role for Janssen, Genentech, AstraZeneca, Bayer, Myovant Sciences, Promontory Therapeutics, BMS, Novartis, and Astellas Pharma. Professional medical writing and editorial assistance were provided by Benjamin Levine, PhD, Keri Wellington, PhD, and Ronnie Lewis, MSc, of Spark (a division of Prime, New York, USA).
PubMed
